Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
List view / Grid view
Filter the results
A study has shown that the COVID-19 pandemic has resulted in a high level of research donations, making the condition the third most funded disease on average by year.
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
Researchers have used virtual reality (VR) to control how drugs bind to their protein targets, which they say could be useful for designing new treatments.
A group of researchers, led by Professor Zucai Suo, have revealed the mode of action of two HIV drugs and identified how resistance can develop, which they say could lead to improved drug design in the future.
According to a new study, apolipoprotein A-I binding protein restricts HIV-1 replication by targeting lipid rafts and reducing virus-cell fusion.
A new study has shown in three dimensions how drugs bind to HIV, which could be used to improve the design of drugs or develop novel therapies.
Two possible therapeutic approaches to cause dormant HIV to re-emerge from their latency reservoir could provide new possible avenues to a cure for HIV, says research.
A study in mice has found that a compound modelled on a protein found in bananas safely protects against multiple strains of the influenza virus.
A study has shown that administering two antibodies soon after birth can prevent HIV from developing in rhesus macaques.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
Gene editing using the CRISPR system has been established as the most powerful tool in the search for new drugs and is now being exploited for therapeutic purposes. Here, Pushpanathan Muthuirulan discusses the promises and wider opportunities of using CRISPR technology to open up the possibility of large-scale screening of…
Immunogens can be used to coax the immune system into producing broadly neutralising antibodies to fight a HIV infection, making a vaccine against the condition more likely, say researchers.
Researchers have developed a novel peptide with a prolonged half-life that has demonstrated success in rhesus monkeys and mice for inhibiting HIV infections.